# Revelation Biosciences, Inc.: financial statements, quarterly

REVB · Nasdaq · CIK 1810560 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/revb.md) · [Financials](/companies/revb/financials.md) · [Filings](/companies/revb/filings.md) · [Insiders](/companies/revb/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/revb/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $k | [1,651](/filings/0000950170-24-124036.md) | [1,060 d](/filings/0000950170-25-034584.md) | [718](/filings/0000950170-25-066897.md) | [1,395](/filings/0000950170-25-105284.md) | [831](/filings/0001193125-25-269450.md) | [606 d](/filings/0001193125-26-076552.md) | [859](/filings/0001193125-26-211871.md) | [1,318](/filings/0001193125-26-337967.md) | [923](/filings/0001193125-25-269450.md) | [964 d](/filings/0001193125-26-076552.md) | [1,377](/filings/0001193125-26-211871.md) | [1,918](/filings/0001193125-26-337967.md) |
| Operating income | $k | [(2,778)](/filings/0000950170-24-124036.md) | [(2,326) d](/filings/0000950170-25-034584.md) | [(1,902)](/filings/0000950170-25-066897.md) | [(2,522)](/filings/0000950170-25-105284.md) | [(1,797)](/filings/0001193125-25-269450.md) | [(1,754) d](/filings/0001193125-26-076552.md) | [(2,095)](/filings/0001193125-26-211871.md) | [(2,461)](/filings/0001193125-26-337967.md) | [(1,943)](/filings/0001193125-25-269450.md) | [(2,572) d](/filings/0001193125-26-076552.md) | [(3,093)](/filings/0001193125-26-211871.md) | [(3,662)](/filings/0001193125-26-337967.md) |
| Income tax | $k | [0.0](/filings/0000950170-24-124036.md) | [0.0 d](/filings/0000950170-25-034584.md) | [0.0](/filings/0000950170-25-066897.md) | [0.0](/filings/0000950170-24-108797.md) | [0.0](/filings/0001193125-25-269450.md) | [0.0 d](/filings/0001193125-26-076552.md) | [0.0](/filings/0000950170-25-066897.md) | [0.0 d](/filings/0000950170-25-105284.md) | [0.0](/filings/0001193125-25-269450.md) | [0.0 d](/filings/0001193125-26-076552.md) | not reported | not reported |
| Net income | $k | [(2,628)](/filings/0000950170-24-124036.md) | [(2,203) d](/filings/0000950170-25-034584.md) | [(2,681)](/filings/0001193125-25-269450.md) | [(8,390)](/filings/0001193125-25-269450.md) | [(2,242)](/filings/0001193125-25-269450.md) | [(1,726) d](/filings/0001193125-26-076552.md) | [(2,051)](/filings/0001193125-26-337967.md) | [(2,444)](/filings/0001193125-26-337967.md) | [(1,907)](/filings/0001193125-25-269450.md) | [(2,511) d](/filings/0001193125-26-076552.md) | [(3,009)](/filings/0001193125-26-337967.md) | [(3,323)](/filings/0001193125-26-337967.md) |
| Diluted EPS | $ per share | [(9.94)](/filings/0000950170-24-124036.md) | not reported | [(39.37)](/filings/0000950170-25-066897.md) | [(246.27)](/filings/0000950170-25-105284.md) | [(40.15)](/filings/0001193125-25-269450.md) | not reported | [(25.34)](/filings/0001193125-26-211871.md) | [(28.04)](/filings/0001193125-26-337967.md) | [(1.77)](/filings/0001193125-25-269450.md) | not reported | [(2.71)](/filings/0001193125-26-211871.md) | [(0.87)](/filings/0001193125-26-337967.md) |
| Basic EPS | $ per share | [(9.94)](/filings/0000950170-24-124036.md) | not reported | [(39.37)](/filings/0000950170-25-066897.md) | [(246.27)](/filings/0000950170-25-105284.md) | [(40.15)](/filings/0001193125-25-269450.md) | not reported | [(25.34)](/filings/0001193125-26-211871.md) | [(28.04)](/filings/0001193125-26-337967.md) | [(1.77)](/filings/0001193125-25-269450.md) | not reported | [(2.71)](/filings/0001193125-26-211871.md) | [(0.87)](/filings/0001193125-26-337967.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [14.0](/filings/0000950170-23-062025.md) | [12.0](/filings/0000950170-25-034584.md) | [14.6](/filings/0000950170-24-108796.md) | [12.1](/filings/0000950170-24-108797.md) | [6.5](/filings/0000950170-24-124036.md) | [6.5](/filings/0001193125-26-076552.md) | [3.7](/filings/0000950170-25-066897.md) | [5.2](/filings/0000950170-25-105284.md) | [12.7](/filings/0001193125-25-269450.md) | [10.7](/filings/0001193125-26-337967.md) | [14.1](/filings/0001193125-26-211871.md) | [11.5](/filings/0001193125-26-337967.md) |
| Current assets | $m | [14.1](/filings/0000950170-23-062025.md) | [12.1](/filings/0000950170-25-034584.md) | [14.6](/filings/0000950170-24-108796.md) | [12.2](/filings/0000950170-24-108797.md) | [6.7](/filings/0000950170-24-124036.md) | [6.6](/filings/0001193125-26-076552.md) | [3.9](/filings/0000950170-25-066897.md) | [5.4](/filings/0000950170-25-105284.md) | [12.8](/filings/0001193125-25-269450.md) | [10.8](/filings/0001193125-26-337967.md) | [14.2](/filings/0001193125-26-211871.md) | [11.7](/filings/0001193125-26-337967.md) |
| Total assets | $m | [14.2](/filings/0000950170-23-062025.md) | [12.2](/filings/0000950170-25-034584.md) | [14.7](/filings/0000950170-24-108796.md) | [12.3](/filings/0000950170-24-108797.md) | [6.7](/filings/0000950170-24-124036.md) | [6.6](/filings/0001193125-26-076552.md) | [4.0](/filings/0000950170-25-066897.md) | [5.4](/filings/0000950170-25-105284.md) | [12.9](/filings/0001193125-25-269450.md) | [11.6](/filings/0001193125-26-337967.md) | [15.0](/filings/0001193125-26-211871.md) | [12.5](/filings/0001193125-26-337967.md) |
| Current liabilities | $m | [5.4](/filings/0000950170-23-062025.md) | [5.6](/filings/0000950170-25-034584.md) | [5.2](/filings/0000950170-24-108796.md) | [11.1](/filings/0000950170-24-108797.md) | [4.1](/filings/0000950170-24-124036.md) | [1.9](/filings/0001193125-26-076552.md) | [1.1](/filings/0000950170-25-066897.md) | [1.6](/filings/0000950170-25-105284.md) | [1.9](/filings/0001193125-25-269450.md) | [2.0](/filings/0001193125-26-337967.md) | [1.4](/filings/0001193125-26-211871.md) | [1.9](/filings/0001193125-26-337967.md) |
| Total liabilities | $m | [5.4](/filings/0000950170-23-062025.md) | [5.6](/filings/0000950170-25-034584.md) | [5.2](/filings/0000950170-24-108796.md) | [11.1](/filings/0000950170-24-108797.md) | [4.1](/filings/0000950170-24-124036.md) | [1.9](/filings/0001193125-26-076552.md) | [1.1](/filings/0000950170-25-066897.md) | [1.6](/filings/0000950170-25-105284.md) | [1.9](/filings/0001193125-25-269450.md) | [2.7](/filings/0001193125-26-337967.md) | [2.1](/filings/0001193125-26-211871.md) | [2.4](/filings/0001193125-26-337967.md) |
| Shareholders' equity | $m | [8.8](/filings/0000950170-24-124036.md) | [6.6](/filings/0001193125-26-076552.md) | [9.5](/filings/0001193125-25-269450.md) | [1.1](/filings/0001193125-25-269450.md) | [2.7](/filings/0001193125-25-269450.md) | [4.7](/filings/0001193125-26-337967.md) | [2.9](/filings/0001193125-26-337967.md) | [3.8](/filings/0001193125-26-337967.md) | [11.0](/filings/0001193125-25-269450.md) | [8.9](/filings/0001193125-26-337967.md) | [13.0](/filings/0001193125-26-337967.md) | [10.1](/filings/0001193125-26-337967.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,717) d](/filings/0000950170-24-124036.md) | [(2,003) d](/filings/0000950170-25-034584.md) | [(2,838)](/filings/0000950170-25-066897.md) | [(2,479) d](/filings/0000950170-25-105284.md) | [(9,257) d](/filings/0001193125-25-269450.md) | [(3,748) d](/filings/0001193125-26-076552.md) | [(2,794)](/filings/0001193125-26-211871.md) | [(1,919) d](/filings/0001193125-26-337967.md) | [(1,589) d](/filings/0001193125-25-269450.md) | [(1,967) d](/filings/0001193125-26-076552.md) | [(3,215)](/filings/0001193125-26-211871.md) | [(2,557) d](/filings/0001193125-26-337967.md) |
| Capital expenditure | $k | [0.0 d](/filings/0000950170-24-124036.md) | not reported | [19.2](/filings/0000950170-25-066897.md) | [0.0 d](/filings/0000950170-25-105284.md) | [17.7 d](/filings/0001193125-25-269450.md) | [(17.7) d](/filings/0001193125-26-076552.md) | not reported | not reported | not reported | not reported | [71.9](/filings/0001193125-26-211871.md) | [39.6 d](/filings/0001193125-26-337967.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [612](/filings/0000950170-23-062025.md) | [166](/filings/0000950170-24-108796.md) | [248](/filings/0000950170-24-108797.md) | [265](/filings/0000950170-24-124036.md) | [68.1](/filings/0000950170-25-066897.md) | [34.1](/filings/0000950170-25-105284.md) | [55.8](/filings/0001193125-25-269450.md) | [80.9](/filings/0001193125-26-211871.md) | [201](/filings/0001193125-26-337967.md) | [2,645](/filings/0001193125-25-269450.md) | [3,208](/filings/0001193125-26-211871.md) | [3,829](/filings/0001193125-26-337967.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 3,983,416 at 2026-08-03, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-337967.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.